| ObjectiveIn this study,the serum ELAVL1 levels of all subjects was measured to clarify its relationship with clinical related indicators,and further explore the correlation between serum ELAVL1 level and non-alcoholic fatty liver disease(NAFLD),which may provide certain reference value for the early diagnosis and treatment of NAFLD.MethodsA total of 124 patients who met the inclusion and exclusion criteria in Gansu Provincial People’s Hospital from October 2021 to October 2022 were selected as the research objects,and they were divided into NAFLD group(62 cases)and non-NAFLD group(62cases).Physical examination and medical history were collected,including age,gender,height,weight,blood pressure,drinking history,past medical history and medication history.Two fasting antecubital venous blood samples were collected from all subjects.One blood sample was sent to the laboratory center of our hospital to complete the detection of relevant clinical indicators,and another blood sample was tested for the serum ELAVL1 level by enzyme-linked immunosorbent assay(ELISA).SPSS 26.0 and Graph Pad Prism 8.0 software were used for data processing and drawing.Results1.SBP,DBP,BMI,FPG,FINS,TC,TG,LDL-C,Ty G index,HOMA-IR index,ALT,AST,GGT,ALP,UA,UA/Cr,TSH,T4,FT3 and CRP in NAFLD group were higher than those in non-NAFLD group,and the difference was statistically significant(P<0.05).HDL-C,ISI index,AST/ALT and ELAVL1 in NAFLD group were lower than those in the non-NAFLD group,and the difference was statistically significant(P<0.05).There were no significant differences in gender,age,TP,ALB,DBIL,IBIL,TBA,BUN,Cr,BUN/Cr,T3,FT4,CK,CK-MB,LDH,Hcy between the two groups(P>0.05).2.All subjects were grouped according to BMI level.The results showed that compared with BMI<24kg/m~2group,the serum ELAVL1 level of BMI≥24kg/m~2group was lowered,and the difference between the two groups was statistically significant(P<0.05).The NAFLD group and the non-NAFLD group were divided into four subgroups according to BMI level.The results showed that compared with non-NAFLD and BMI<24kg/m~2group(group D),NAFLD and BMI≥24kg/m~2group(group A)had significantly lower serum ELAVL1concentration.The difference between the two groups was statistically significant(P<0.05).3.There was no gender difference in serum ELAVL1 level in all subjects(P>0.05).However,NAFLD group and non-NAFLD group were further divided into 4 subgroups according to gender.The results showed that compared with non-NAFLD female group(H group),NAFLD male group(E group)and NAFLD male group(E group)had significantly lower serum ELAVL1 level,and the difference between the two groups was statistically significant(P<0.05).4.The serum ELAVL1 level was negatively correlated with BMI,TC,LDL-C,T4 and FT3,and positively correlated with AST/ALT,but not correlated with other indicators.Multiple linear stepwise regression analysis showed that BMI,TG and FT3 were independent influencing factors for ELAVL1.5.The serum ELAVL1 level of all research subjects were divided into quartiles.The results showed that the prevalence of NAFLD gradually decreased with the increase of serum ELAVL1 level,trend test(P<0.001).Without adjustment,serum ELAVL1 level was a protective factor for NAFLD.After adjustment for age,sex,and BMI,serum ELAVL1 level in the fourth quartile group remained a protective factor for NAFLD.6.The ROC curve showed that the area under the curve of serum ELAVL1 for predicting NAFLD was 0.696,the 95%confidence interval was 0.605-0.787,the maximum Youden index was 0.307,the cutoff point was 112.967pg/ml,the sensitivity was 0.355,and the specificity was 0.952.ConclusionThis study shows that compared with non-NAFLD patients,the serum ELAVL1 level is decreased in NAFLD patients,and ELAVL1 may be a protective factor for NAFLD,which may provide a new reference value for the early diagnosis and treatment of NAFLD. |
PDF Full Text Request